New Oral Compound Shows Promise in Weight Loss for Obese Mice

A team of researchers from the University of California, Berkeley, has found a promising oral compound, TOFA, that led to significant weight loss in obese mice. Unlike other treatments, TOFA boosts energy expenditure rather than reducing appetite, according to a study published in Science Advances.

The compound reduced the body weight of mice by an average of 18% while preserving lean mass. This differs from popular weight-loss medications like semaglutide that partially work by decreasing food intake, causing some patients to face gastrointestinal side effects and muscle loss.

Key Findings and Implications

TOFA operates within cells, preventing enzymes involved in lipid production while activating receptors that enhance fat burning and energy production. Mice treated with TOFA showed up to 18% higher energy expenditure without reducing activity levels or increasing body temperature dangerously.

Combining TOFA with existing obesity drugs like semaglutide or tirzepatide resulted in greater weight loss and improved blood sugar, insulin, and triglyceride levels compared to using the drugs alone. Notably, mice on TOFA maintained near-normal body weights after treatment ended, contrary to those on semaglutide who regained weight quickly.

“Muscle mass is crucial for daily function and combating aging,” stated Dr. Leslie Pristas, a bariatric surgeon. “Avoiding muscle loss during weight loss is beneficial.”

Additional Potential Benefits

TOFA also showed promise for metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. Mice treated with TOFA had reduced liver fat, inflammation, and fibrosis without increased triglyceride levels, which has been a concern with similar drugs.

Study Limitations

The research was conducted solely on male mice, and further studies are necessary to assess the effects on female mice. The compound has not been tested on humans yet, leaving questions about proper dosing, long-term safety, and potential side effects unanswered. Dr. Pristas cautioned that while early results are encouraging, possible side effects in humans must be considered.

“If it sounds too good to be true, it’s probably too good to be true,” she added, emphasizing a careful approach.

The researchers mentioned involvement with ReRx Therapeutics, which has the option to develop the discovery further. Continued exploration could lead to new treatment avenues, benefiting individuals when used alone or with other therapies.